Tivozanib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Tivozanib. Educational only — not medical advice.
Labeled uses
FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
Source: FDA labeling via NIH DailyMed (set de77155c…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.